Matching articles for "Izervay"

Valeda Light Delivery System for Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • January 20, 2025;  (Issue 1720)
The FDA has authorized use of the Valeda Light Delivery System (LumiThera), a multiwavelength photobiomodulation (PBM) device, to improve visual acuity in patients with dry age-related macular degeneration...
The FDA has authorized use of the Valeda Light Delivery System (LumiThera), a multiwavelength photobiomodulation (PBM) device, to improve visual acuity in patients with dry age-related macular degeneration (AMD) who have best-corrected visual acuity (BCVA) of 20/32 to 20/70.
Med Lett Drugs Ther. 2025 Jan 20;67(1720):9-10 | Show Full IntroductionHide Full Introduction

Drugs for Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • January 6, 2025;  (Issue 1719)
Age-related macular degeneration (AMD) has two major forms: dry or non-neovascular (~90% of patients) and wet or neovascular (~10% of...
Age-related macular degeneration (AMD) has two major forms: dry or non-neovascular (~90% of patients) and wet or neovascular (~10% of patients).
Med Lett Drugs Ther. 2025 Jan 6;67(1719):1-5 | Show Full IntroductionHide Full Introduction

Avacincaptad Pegol (Izervay) for Geographic Atrophy in Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • January 22, 2024;  (Issue 1694)
The FDA has approved the complement C5 inhibitor avacincaptad pegol (Izervay – Iveric) for intravitreal treatment of geographic atrophy (GA) secondary to age-related macular degeneration...
The FDA has approved the complement C5 inhibitor avacincaptad pegol (Izervay – Iveric) for intravitreal treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Avacincaptad pegol is the second complement inhibitor to be approved in the US for this indication; pegcetacoplan (Syfovre), a complement C3 and C3b inhibitor, was approved earlier.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):15-6 | Show Full IntroductionHide Full Introduction